PepTrackevidence-graded reference
TB-500 (Thymosin beta-4 fragment)
fig.1 — stylized molecular motif
Healing & recovery

TB-500 (Thymosin beta-4 fragment)

Ac-LKKTETQ · Tbeta4 17-23

BPC-157's inseparable co-star; the other half of the 'Wolverine' recovery stack.

Evidence
Danimal-only
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
Healing & recovery
Route
Subcutaneous · Intramuscular
Demand rank
#6 most-searched
01Dosing & Protocol
Typical · reference only
~2-2.5 mg per injection, weekly (loading then maintenance)
Titration
No real titration; some start ~2 mg to gauge tolerance
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5 mg/mL; 2.5 mg = 50 U, 2 mg = 40 U on U-100. mg-dosed (mcg confusion = 1000x).
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. WADA S0 prohibited at all times.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 Apr 2026
PCAC review
2026-07-23/24
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows

Animal-only for consumer use. The sold molecule is a 7-aa FRAGMENT distinct from full-length Tbeta4 used in (unrelated, unpublished) human programs. Zero completed efficacy RCTs. Viral '4.8% LVEF' stat is a vendor-blog fabrication.

04Safety
Contraindications
  • Active/recent cancer (angiogenesis; ~5 yr commonly cited)
  • Pregnancyhard stop
  • WADA athletes/military
  • Bleeding disorders (cautious)
Key interactions
  • Anticoagulants/antiplatelets (plausible, unvalidated)
  • VEGF inhibitors / antiangiogenic chemo (mechanistically opposed - double contraindication)
Serious signals
  • Pro-angiogenic/cancer signal (theoretical)
  • Fragment PK unknown in humans
  • Marketed fragment may be inactive species
Monitoring
No validated cadence; cancer screening (harm-reduction).
05Related in Healing & recovery
BPC-157
animal-only
grade D →
06Sources
1ClinicalTrials.gov NCT07487363
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high
← All peptides
Healing & recovery

TB-500 (Thymosin beta-4 fragment)

Ac-LKKTETQ · Tbeta4 17-23

BPC-157's inseparable co-star; the other half of the 'Wolverine' recovery stack.

Evidence
D
animal-only
Status
Removed from Cat 2 · pending PCAC
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous · Intramuscular
Community / anecdotal
Demand
#6
most-searched
WADA
Prohibited
tested athletes — avoid
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

~2-2.5 mg per injection, weekly (loading then maintenance)

Worked reconstitution example

10 mg vial + 2 mL BAC = 5 mg/mL; 2.5 mg = 50 U, 2 mg = 40 U on U-100. mg-dosed (mcg confusion = 1000x).

Titration

No real titration; some start ~2 mg to gauge tolerance

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. WADA S0 prohibited at all times.
StatusRemoved from Cat 2 · pending PCAC
503A bulksNot on the bulks list
Category 2 (2026)Removed from Category 2 Apr 2026
PCAC review2026-07-23/24
WADAProhibited (S0)
03

Evidence — the honest read

Danimal-only

Animal-only for consumer use. The sold molecule is a 7-aa FRAGMENT distinct from full-length Tbeta4 used in (unrelated, unpublished) human programs. Zero completed efficacy RCTs. Viral '4.8% LVEF' stat is a vendor-blog fabrication.

04

Safety

Contraindications
  • Active/recent cancer (angiogenesis; ~5 yr commonly cited)
  • Pregnancyhard stop
  • WADA athletes/military
  • Bleeding disorders (cautious)
Key interactions
  • Anticoagulants/antiplatelets (plausible, unvalidated)
  • VEGF inhibitors / antiangiogenic chemo (mechanistically opposed - double contraindication)
Serious signals
  • Pro-angiogenic/cancer signal (theoretical)
  • Fragment PK unknown in humans
  • Marketed fragment may be inactive species
Monitoring

No validated cadence; cancer screening (harm-reduction).

06

Sources

01ClinicalTrials.gov NCT07487363
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high